Key Takeaways INSM shares plunged nearly 20% after the phase IIb BiRCh study missed both primary and secondary endpoints.Insmed ended Brinsupri development in CRSsNP after no benefit versus placebo despite good tolerability.INSM acquired INS1148 from Opsidio and plans mid-stage studies in interstitial lung disease and asthma.Shares of Insmed (INSM) lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a mid-stage study evaluating Brinsupri (brensocatib) in chronic r ...